Am I a Candidate for Stem Cell Therapy? A Doctor’s Guide to Evaluating Bone-on-Bone Knee Arthritis

---

If you’ve been told your knee is “bone on bone” and that a joint replacement is your only option, we want you to pause before accepting that conclusion.

That diagnosis —as frightening as it sounds— is not a closed door. For many patients we evaluate at our clinics across Denver, Fort Collins, and Colorado Springs, it’s actually the beginning of a different conversation: one about what your knee can still do, and what biology can do to support it.

This guide walks you through exactly how we assess severe knee degeneration, which patients typically respond well to regenerative treatment, such as stem cell therapy, and what a realistic outcome looks like —so you can make an informed decision, not a fear-driven one.

---

What Does “Bone on Bone” Actually Mean — And Why Doctors May Be Wrong About Your Options

Here’s what that image does not show you: the full biological state of the tissue.

X-rays capture bone density and joint geometry. They do not capture the viability of the remaining cartilage matrix, the health of the surrounding synovial tissue, or the blood supply to the joint. Two patients with nearly identical X-rays can have very different biological environments inside that knee, and that difference is exactly what determines whether regenerative treatment is a viable path.

The clinical reality is that “bone on bone” exists on a spectrum. Kellgren-Lawrence Grade 4 osteoarthritis (the most severe classification) does represent advanced degeneration. But even within that grade, patients vary significantly in their remaining tissue viability, inflammatory load, and regenerative potential. A formal evaluation —not a quick review of an old X-ray— is the only way to determine where you fall on that spectrum.

“The X-ray tells us the geography of the joint. The full evaluation tells us whether the biological environment can support healing.” — Dr. Joel Cherdack

---

How We Evaluate Whether Your Knee Can Respond to Regenerative Treatment

Candidacy for stem cell therapy is not a binary yes or no. It’s a clinical judgment built from multiple data points and it’s one of the most important conversations we have with every new patient.

What We Look for on Your X-Ray and MRI

We begin with imaging, but we read it differently than a surgeon preparing for a replacement.

On an X-ray, we assess the degree of joint space narrowing, the presence of bone spurs (osteophytes), and any subchondral bone changes. On an MRI —which we strongly recommend for any candidate evaluation— we can visualize the actual cartilage thickness, identify areas of bone marrow edema, assess the integrity of the meniscus, and evaluate the soft tissue environment surrounding the joint.

What we’re looking for is not perfection. We’re looking for enough biological substrate to work with. A joint that retains some cartilage matrix, even if thinned or irregular, typically offers more regenerative opportunity than one that has undergone complete subchondral bone remodeling throughout the entire compartment.

The Patient Candidacy Matrix — Age, Health, and Which Cells Work Best for You

One of the most important —and most overlooked— aspects of regenerative medicine is that not every patient should receive the same type of cells. The source of your stem cells matters enormously, and the right choice depends on your individual biology.

Here is how we typically approach that decision:

Patient Profile	Recommended Cell Source	Clinical Rationale
Healthy adult, age 40–60, active lifestyle, no metabolic disease	Autologous (your own bone marrow + adipose)	Highest biological compatibility; your cells carry no immune rejection risk and retain strong regenerative signaling in a healthy metabolic environment
Active adult, age 60–70, mild metabolic conditions (e.g., well-controlled diabetes)	Combination autologous + donor supplementation	Your own cells provide compatibility; donor cells supplement volume and growth factor concentration, where autologous yield may be reduced
Patient 70+, sedentary, significant metabolic burden (obesity, autoimmune conditions, poorly controlled diabetes)	Umbilical cord-derived donor cells	Autologous cell quality and quantity may be significantly reduced by age and systemic inflammation; ethically sourced donor cells provide a more consistent regenerative dose
Severe Grade 4 OA with complete joint destruction across all compartments	Surgical consultation recommended	Regenerative therapy works best when there is a viable biological environment to support repair; complete mechanical failure may require structural intervention first

This matrix is a general clinical framework, not a guaranteed protocol. Every patient we evaluate receives an individualized assessment because the goal is to match the treatment to your biology, not fit your biology into a standard treatment.

---

The Three Biological Tools We Use — And Why They Work Together

A single injection of any one substance —stem cells, PRP, or exosomes— is not how we approach severe osteoarthritis. The most effective regeneration of damaged tissue comes from a powerful synergy of these components working together, each amplifying the others.

Your Own Stem Cells: Bone Marrow and Adipose Tissue

When you are a good candidate for autologous treatment, we harvest mesenchymal stem cells from two sources: your bone marrow (typically from the iliac crest of the pelvis) and your adipose (fat) tissue, usually from the abdomen or flank.

Why two sources? Because each population has different concentrations of specific regenerative cell types and growth factors. Bone marrow-derived cells tend to have strong chondrogenic (cartilage-forming) potential. Adipose-derived cells typically yield higher raw stem cell counts and carry potent anti-inflammatory signaling molecules. Together, they provide a more complete biological toolkit than either source alone. That dual-source approach is one of the key differentiators in how we treat patients across our Front Range clinics.

Donor Stem Cells: When and Why We Use Umbilical Cord-Derived Cells

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are collected from Wharton’s jelly —the connective tissue of the umbilical cord— following healthy, full-term births, with full informed consent from the donating family. No embryonic tissue is used, and no harm comes to the mother or infant.

These cells are ethically sourced, extensively screened, and processed by FDA-registered laboratories. For patients whose own cell quality or quantity may be limited by age or systemic health conditions, donor cells can provide a consistent, high-concentration regenerative dose.

It’s worth noting that while UC-MSCs are generally considered immunologically privileged (meaning they carry a low risk of rejection), all donor cell treatments carry some degree of biological variability. We discuss these considerations openly with every patient during their evaluation.

Platelet-Rich Plasma (PRP): The Activator That Makes Stem Cells Work

Think of stem cells as seeds. PRP is the fertilizer.

Platelet-Rich Plasma is derived from your own blood, drawn, centrifuged to concentrate the platelets, and then injected alongside the stem cells. Platelets are not just clotting agents; they are dense packets of growth factors, including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), and Vascular Endothelial Growth Factor (VEGF).

These growth factors signal the stem cells to differentiate, proliferate, and migrate to areas of damage. Without this platelet-rich plasma activation, stem cells introduced into a degenerated joint environment may remain relatively dormant. With it, they have a clear biological directive. This is why we virtually always use PRP as part of our regenerative knee injection treatments. 

Exosomes: The Cellular Signals That Accelerate Healing

Exosomes are nanoscale vesicles —essentially tiny communication packets— secreted by stem cells. They carry microRNA, proteins, and signaling molecules that instruct surrounding cells to reduce inflammation, increase collagen production, and initiate tissue repair.

A typical therapeutic exosome preparation may contain several billion exosomes per dose, each loaded with growth factors including VEGF, TGF-β, and hepatocyte growth factor (HGF). Research comparing stem cell therapy with and without exosome supplementation suggests that exosomes may meaningfully amplify the regenerative signal, particularly in environments with high inflammatory burden, which is common in advanced osteoarthritis.

Exosomes do not replace stem cells. They extend and amplify their effect and in a severely degenerated joint, that amplification can be the difference between a modest response and a meaningful one.

---

The Hidden Factor Most Clinics Don’t Talk About: Blood Flow and Angiogenesis

Here is something that rarely appears in competitor content, but that we consider essential to understand: cartilage itself is avascular, meaning it has no direct blood supply. It receives nutrients through diffusion from the synovial fluid and the underlying subchondral bone.

In advanced osteoarthritis, that nutrient delivery system is severely compromised. The subchondral bone becomes sclerotic (hardened and less permeable), synovial inflammation impairs fluid quality, and the microvasculature surrounding the joint deteriorates. Without adequate blood flow, even a well-executed stem cell injection is working in a nutrient-depleted environment.

This is where Microvascular Tissue (MVT) becomes relevant. MVT is derived from porcine (pig) bladder matrix, which is a biological scaffold that has been FDA-cleared for wound healing applications. Its primary mechanism in the joint environment is angiogenesis: the formation of new capillary networks that restore blood flow to the periarticular tissue.

When we restore microvascular perfusion to the tissues surrounding the joint, we are essentially reopening the supply lines that stem cells and growth factors need to do their work. Think of it as clearing a blocked irrigation system before planting: the seeds have far better conditions to take root.

This is a component of treatment that many single-injection clinics do not include, and in our clinical experience, it is a meaningful contributor to durable outcomes in patients with advanced degeneration.

---

What Can You Realistically Expect? Pain Relief, Timeline, and Honest Outcomes

We will always be direct with you about this, because unrealistic expectations are unfair to patients and ultimately harmful to the field of regenerative medicine.

Stem cell therapy for advanced knee osteoarthritis is not a guaranteed cure. It is a biologically active intervention that, in appropriately selected patients, may significantly reduce pain, improve function, and slow the progression of degeneration potentially delaying or avoiding joint replacement surgery.

In patients who respond well, improvements typically develop over a period of 4 to 12 weeks as the biological processes unfold. Benefits often continue to develop for up to 3 months post-treatment and, in many cases, are maintained for multiple years. Patients frequently report being able to return to activities —hiking Colorado’s trails, skiing, staying active— that had become too painful to continue.

What you should expect in the timeline:

• Weeks 1–2: Possible mild injection-site soreness; the inflammatory phase of healing begins
• Weeks 3–6: Initial anti-inflammatory effects of PRP typically become noticeable; some patients report early pain reduction
• Weeks 6–12: Stem cell differentiation and tissue remodeling progress; mobility improvements often emerge in this window
• Months 3–6: Maximum benefit is typically reached; outcomes stabilize

Not every patient achieves the same result. Patients with more severe degeneration, significant metabolic comorbidities, or advanced age may experience more modest improvements. We will tell you honestly during your evaluation what the realistic range of outcomes looks like for your specific profile. 

---

What Are the Risks, and Who Is NOT a Good Candidate?

YMYL-compliant medicine requires us to be as transparent about risks as we are about benefits. Here is an honest accounting.

Potential risks and side effects include temporary injection-site pain or swelling (common and typically resolving within days), a low risk of infection at the injection site, and the possibility that the treatment produces minimal or no measurable improvement. Systemic adverse reactions to autologous cells are rare, given that your own biological material is being used; donor cell protocols carry a slightly higher (though still low) risk of immune response.

Patients who are typically not good candidates include those with:

• Complete, multi-compartmental joint destruction with no remaining viable cartilage matrix
• Active joint infection or systemic infection
• Uncontrolled autoimmune disease actively attacking joint tissue
• Certain blood-clotting disorders or patients on anticoagulation therapy (requires physician review)
• Active malignancy

Conditions like well-controlled diabetes, mild-to-moderate obesity, or prior cortisone injections do not automatically disqualify a patient, but they do affect the treatment protocol and our candidacy assessment. This is precisely why a formal evaluation is essential before any decision is made.

---

What Does This Cost, and Does Insurance Cover It?

Regenerative medicine procedures, including stem cell therapy, PRP, and exosome treatments, are currently classified as elective and are not covered by Medicare or most private insurance plans. This is the honest reality of where the field stands from a reimbursement perspective.

The out-of-pocket costs for orthobiologics vary based on the complexity of the protocol — whether autologous or donor cells are used, whether exosomes are included, and how many joints are being treated. We encourage you to ask specific cost questions during your consultation, so you have a complete financial picture before making any decision.

To make treatment accessible, we accept CareCredit, AdvanceCare, and Financing Solutions. HSA/FSA superbills are available, which may allow partial reimbursement through your health savings account. We want cost to be a factor you can plan for — not a barrier that prevents you from even exploring your options.

---

What Are the Risks, and Who Is NOT a Good Candidate?

Pre-Consultation Candidacy Checklist
Before your evaluation, consider gathering the following:

• ☐ Most recent knee X-rays (within 18 months) or MRI report
• ☐ List of current medications, including any blood thinners or immunosuppressants
• ☐ Documentation of prior knee treatments (cortisone, hyaluronic acid, prior surgery)
• ☐ Summary of current activity level and functional limitations
• ☐ Any relevant metabolic health records (HbA1c, BMI, autoimmune diagnoses)

Bringing this information to your consultation allows us to give you a far more specific and useful candidacy assessment.

---

What To Do Next

If you’ve read this far, you’re doing exactly what a well-informed patient should do — gathering objective information before making a major medical decision.

The next step is a formal joint space evaluation with our clinical team. This is not a sales call. It’s a clinical conversation where we review your imaging, discuss your health history, and give you an honest assessment of whether regenerative treatment is a realistic path for your specific knee — or whether a different approach makes more sense for you.

We evaluate patients at three Front Range locations: Denver (455 Sherman St), Fort Collins (155 Boardwalk Dr), and Colorado Springs (5040 Corporate Plaza Dr). Colorado winters are hard on arthritic joints — barometric pressure drops and cold temperatures are well-documented triggers for increased joint pain and stiffness. If your symptoms have been worsening with the season, this may be the right time to get a clear picture of your options.

Schedule your free consultation today →

Or call us directly:

• Denver: 720-583-1648
• Fort Collins: 970-578-3636
• Colorado Springs: 719-781-3434

You don’t have to choose between living in pain and going under the knife. Let’s find out together what your knee can do.